Tailored Antiplatelet Therapy Following PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5276 participants.

Also called NCT01742117

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,276 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01742117
Main results
  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial JAMA, 2020-08-25 DOI, PubMed 32840598, PMC7448831 Not in the PMC Open Access subset.
Other papers using this trial's data
  • Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention JACC. Cardiovascular interventions, 2023-04-10 DOI, PubMed 37045502, PMC10498663 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI Clinical and translational science, 2026-07 DOI, PubMed 42427167, PMC13351311 In the PMC Open Access subset under CC BY-NC-ND.
  • Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study Cardiovascular drugs and therapy, 2024-06 DOI, PubMed 36445624, PMC10225474 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial Journal of the American Heart Association, 2022-06-21 DOI, PubMed 35699175, PMC9238632 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Mexico, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01742117. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2020-10-31 (actual). Results posted on 2021-11-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tailored Antiplatelet Therapy Following PCI
Acronym
TAILOR-PCI
Condition
Acute Coronary Syndrome
Condition
Stenosis
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Ticagrelor
Lead sponsor
Mayo Clinic (class: other)
Collaborator
Spartan Bioscience Inc. (class: industry)
Collaborator
Applied Health Research Centre (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01742117
Content hash
01c6822511c3a5133370272a70de09ab5f68d8bab161ef48e72cb958d416dbe8